Alexander Belkin
Internal Medicine · Providence, RINPI 1346701653
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,167 and has fallen 78.3% since, to $469 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $80.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$856
- Janssen Scientific Affairs, LLC$692
- Johnson & Johnson$568
- Gilead$558
- E.r. Squibb & Sons, L.L.C.$558
- Rigel Pharmaceuticals, Inc.$394
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,01091%
- Education$5159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 8 | $856 |
| Janssen Scientific Affairs, LLC | 9 | $692 |
| Johnson & Johnson | 12 | $568 |
| Gilead(2 entities) | 5 | $558 |
| E.r. Squibb & Sons, L.L.C. | 6 | $558 |
| Rigel Pharmaceuticals, Inc. | 8 | $394 |
| AbbVie | 4 | $383 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $242 |
| AstraZeneca | 2 | $234 |
| Sanofi | 1 | $133 |
| Progenics Pharmaceuticals, Inc. | 1 | $121 |
| Seagen Inc. | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $106 |
| Eisai Inc. | 1 | $100 |
| ADC Therapeutics America, Inc. | 1 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Sobi, Inc | 1 | $92 |
| Beigene USA, Inc. | 1 | $91 |
| Amgen | 2 | $39 |
| Array Biopharma Inc | 1 | $25 |
| Shield Therapeutics Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,525 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 13 | $240,697 |
| Pilocarpine Hcl | 13 | $469 |
| Anastrozole | 15 | $89 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Providence
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Brian McCauleyProvidence$20K
- Meghan NahassProvidence$19K
- William LangProvidence$15K
- Abdelmoniem MoustafaProvidence$13K
- Khushal ChoudharyProvidence$10K
- Kenneth ChenProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.